# Preventing Stem Cell Transplant Complications With a Blood Separator Machine

> **NCT01866839** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 41 (actual)

## Conditions studied

- MDS (Myelodysplastic Syndrome)
- Myeloproliferative Disorder
- Lymphoma, Non-Hodgkin
- ALL (Acute B-Lymphoblastic Leukemia)
- AML (Acute Myelogenous Leukemia

## Interventions

- **DEVICE:** Graft Manipulation (CD34+ Selection)

## Key facts

- **NCT ID:** NCT01866839
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-29
- **Primary completion:** 2018-05-23
- **Final completion:** 2018-06-28
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01866839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01866839, "Preventing Stem Cell Transplant Complications With a Blood Separator Machine". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT01866839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*